Drugs / Valacilovir
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06474442 Background | Apr 2025 → Dec 2026 expected | stromal keratitis | Shanghai BDgene Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Valacilovir | “Triple-drugs therapy: "Ganciclovir Eye gel+Valacilovir Tablets+Prednisolone Acetate Eye Drops" for 3 weeks.” NCT06474442 ↗ |
| Route | Oral | “Valacilovir Tablets” NCT06474442 ↗ |